Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

Claire Oudin, Patrice Chevallier, Sabine Furst, Thierry Guillaume, Jean El Cheikh, Jacques Delaunay, Luca Castagna, Catherine Faucher, Angela Granata, Raynier Devillier, Christian Chabannon, Benjamin Esterni, Norbert Vey, Mohamad Mohty, Didier Blaise

Research output: Contribution to journalArticle

Abstract

The introduction of reduced intensity/toxicity conditioning regimens has allowed allogeneic hematopoietic cell transplantation to be performed in patients who were previously considered too old or otherwise unfit. Although it led to a reduction in non-relapse mortality, disease control remains a major challenge. We studied the outcome of 165 patients with acute myeloid leukemia (n=124) or myelodysplastic syndrome (n=41) transplanted after conditioning with fludarabine (30 mg/m2/day for 5 days), intravenous busulfan (either 260 mg/m2: reduced intensity conditioning, or 390-520 mg/m2: reduced toxicity conditioning), and rabbit anti-thymoglobulin (2.5 mg/kg/day for2 days). The median age of the patients at transplantation was 56.8 years. The 2-year relapse incidence was 29% (23% versus 39% for patients transplanted in first complete remission and those transplanted beyond first complete remission, respectively; P=0.008). The 2-year progression-free survival rate was 57% (95% CI: 49.9-65). It was higher in the groups with favorable or intermediate cytogenetics than in the group with unfavorable cytogenetics (72.7%, 60.5%, and 45.7%, respectively; P=0.03). The cumulative incidence of grades 2-4 and 3-4 acute graft-versus-host disease at day 100 was 19.3% and 7.9%, respectively. The cumulative incidence of chronic graft-versushost disease at 1 year was 21.6% (severe forms: 7.8%). Non-relapse mortality at 1 year reached 11%. The 2-year overall survival rate was 61.8% (95% CI: 54.8-69.7). Unfavorable karyotype and disease status beyond first complete remission were associated with a poorer survival. This well-tolerated conditioning platform can lead to longterm disease control and offers possibilities of modulation according to disease stage or further development.

Original languageEnglish
Pages (from-to)1762-1768
Number of pages7
JournalHaematologica
Volume99
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Stem Cell Transplantation
Neoplasms
Cytogenetics
Incidence
Survival Rate
Busulfan
Mortality
Myelodysplastic Syndromes
Cell Transplantation
Graft vs Host Disease
Karyotype
Acute Myeloid Leukemia
Disease-Free Survival
Transplantation
Rabbits
Transplants
Recurrence
Survival

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Oudin, C., Chevallier, P., Furst, S., Guillaume, T., El Cheikh, J., Delaunay, J., ... Blaise, D. (2014). Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica, 99(11), 1762-1768. https://doi.org/10.3324/haematol.2014.105981

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. / Oudin, Claire; Chevallier, Patrice; Furst, Sabine; Guillaume, Thierry; El Cheikh, Jean; Delaunay, Jacques; Castagna, Luca; Faucher, Catherine; Granata, Angela; Devillier, Raynier; Chabannon, Christian; Esterni, Benjamin; Vey, Norbert; Mohty, Mohamad; Blaise, Didier.

In: Haematologica, Vol. 99, No. 11, 01.11.2014, p. 1762-1768.

Research output: Contribution to journalArticle

Oudin, C, Chevallier, P, Furst, S, Guillaume, T, El Cheikh, J, Delaunay, J, Castagna, L, Faucher, C, Granata, A, Devillier, R, Chabannon, C, Esterni, B, Vey, N, Mohty, M & Blaise, D 2014, 'Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies', Haematologica, vol. 99, no. 11, pp. 1762-1768. https://doi.org/10.3324/haematol.2014.105981
Oudin, Claire ; Chevallier, Patrice ; Furst, Sabine ; Guillaume, Thierry ; El Cheikh, Jean ; Delaunay, Jacques ; Castagna, Luca ; Faucher, Catherine ; Granata, Angela ; Devillier, Raynier ; Chabannon, Christian ; Esterni, Benjamin ; Vey, Norbert ; Mohty, Mohamad ; Blaise, Didier. / Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. In: Haematologica. 2014 ; Vol. 99, No. 11. pp. 1762-1768.
@article{084df1574cff40bcb1f71d91b0e492ea,
title = "Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies",
abstract = "The introduction of reduced intensity/toxicity conditioning regimens has allowed allogeneic hematopoietic cell transplantation to be performed in patients who were previously considered too old or otherwise unfit. Although it led to a reduction in non-relapse mortality, disease control remains a major challenge. We studied the outcome of 165 patients with acute myeloid leukemia (n=124) or myelodysplastic syndrome (n=41) transplanted after conditioning with fludarabine (30 mg/m2/day for 5 days), intravenous busulfan (either 260 mg/m2: reduced intensity conditioning, or 390-520 mg/m2: reduced toxicity conditioning), and rabbit anti-thymoglobulin (2.5 mg/kg/day for2 days). The median age of the patients at transplantation was 56.8 years. The 2-year relapse incidence was 29{\%} (23{\%} versus 39{\%} for patients transplanted in first complete remission and those transplanted beyond first complete remission, respectively; P=0.008). The 2-year progression-free survival rate was 57{\%} (95{\%} CI: 49.9-65). It was higher in the groups with favorable or intermediate cytogenetics than in the group with unfavorable cytogenetics (72.7{\%}, 60.5{\%}, and 45.7{\%}, respectively; P=0.03). The cumulative incidence of grades 2-4 and 3-4 acute graft-versus-host disease at day 100 was 19.3{\%} and 7.9{\%}, respectively. The cumulative incidence of chronic graft-versushost disease at 1 year was 21.6{\%} (severe forms: 7.8{\%}). Non-relapse mortality at 1 year reached 11{\%}. The 2-year overall survival rate was 61.8{\%} (95{\%} CI: 54.8-69.7). Unfavorable karyotype and disease status beyond first complete remission were associated with a poorer survival. This well-tolerated conditioning platform can lead to longterm disease control and offers possibilities of modulation according to disease stage or further development.",
author = "Claire Oudin and Patrice Chevallier and Sabine Furst and Thierry Guillaume and {El Cheikh}, Jean and Jacques Delaunay and Luca Castagna and Catherine Faucher and Angela Granata and Raynier Devillier and Christian Chabannon and Benjamin Esterni and Norbert Vey and Mohamad Mohty and Didier Blaise",
year = "2014",
month = "11",
day = "1",
doi = "10.3324/haematol.2014.105981",
language = "English",
volume = "99",
pages = "1762--1768",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "11",

}

TY - JOUR

T1 - Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

AU - Oudin, Claire

AU - Chevallier, Patrice

AU - Furst, Sabine

AU - Guillaume, Thierry

AU - El Cheikh, Jean

AU - Delaunay, Jacques

AU - Castagna, Luca

AU - Faucher, Catherine

AU - Granata, Angela

AU - Devillier, Raynier

AU - Chabannon, Christian

AU - Esterni, Benjamin

AU - Vey, Norbert

AU - Mohty, Mohamad

AU - Blaise, Didier

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The introduction of reduced intensity/toxicity conditioning regimens has allowed allogeneic hematopoietic cell transplantation to be performed in patients who were previously considered too old or otherwise unfit. Although it led to a reduction in non-relapse mortality, disease control remains a major challenge. We studied the outcome of 165 patients with acute myeloid leukemia (n=124) or myelodysplastic syndrome (n=41) transplanted after conditioning with fludarabine (30 mg/m2/day for 5 days), intravenous busulfan (either 260 mg/m2: reduced intensity conditioning, or 390-520 mg/m2: reduced toxicity conditioning), and rabbit anti-thymoglobulin (2.5 mg/kg/day for2 days). The median age of the patients at transplantation was 56.8 years. The 2-year relapse incidence was 29% (23% versus 39% for patients transplanted in first complete remission and those transplanted beyond first complete remission, respectively; P=0.008). The 2-year progression-free survival rate was 57% (95% CI: 49.9-65). It was higher in the groups with favorable or intermediate cytogenetics than in the group with unfavorable cytogenetics (72.7%, 60.5%, and 45.7%, respectively; P=0.03). The cumulative incidence of grades 2-4 and 3-4 acute graft-versus-host disease at day 100 was 19.3% and 7.9%, respectively. The cumulative incidence of chronic graft-versushost disease at 1 year was 21.6% (severe forms: 7.8%). Non-relapse mortality at 1 year reached 11%. The 2-year overall survival rate was 61.8% (95% CI: 54.8-69.7). Unfavorable karyotype and disease status beyond first complete remission were associated with a poorer survival. This well-tolerated conditioning platform can lead to longterm disease control and offers possibilities of modulation according to disease stage or further development.

AB - The introduction of reduced intensity/toxicity conditioning regimens has allowed allogeneic hematopoietic cell transplantation to be performed in patients who were previously considered too old or otherwise unfit. Although it led to a reduction in non-relapse mortality, disease control remains a major challenge. We studied the outcome of 165 patients with acute myeloid leukemia (n=124) or myelodysplastic syndrome (n=41) transplanted after conditioning with fludarabine (30 mg/m2/day for 5 days), intravenous busulfan (either 260 mg/m2: reduced intensity conditioning, or 390-520 mg/m2: reduced toxicity conditioning), and rabbit anti-thymoglobulin (2.5 mg/kg/day for2 days). The median age of the patients at transplantation was 56.8 years. The 2-year relapse incidence was 29% (23% versus 39% for patients transplanted in first complete remission and those transplanted beyond first complete remission, respectively; P=0.008). The 2-year progression-free survival rate was 57% (95% CI: 49.9-65). It was higher in the groups with favorable or intermediate cytogenetics than in the group with unfavorable cytogenetics (72.7%, 60.5%, and 45.7%, respectively; P=0.03). The cumulative incidence of grades 2-4 and 3-4 acute graft-versus-host disease at day 100 was 19.3% and 7.9%, respectively. The cumulative incidence of chronic graft-versushost disease at 1 year was 21.6% (severe forms: 7.8%). Non-relapse mortality at 1 year reached 11%. The 2-year overall survival rate was 61.8% (95% CI: 54.8-69.7). Unfavorable karyotype and disease status beyond first complete remission were associated with a poorer survival. This well-tolerated conditioning platform can lead to longterm disease control and offers possibilities of modulation according to disease stage or further development.

UR - http://www.scopus.com/inward/record.url?scp=84908409903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908409903&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.105981

DO - 10.3324/haematol.2014.105981

M3 - Article

C2 - 25085356

AN - SCOPUS:84908409903

VL - 99

SP - 1762

EP - 1768

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 11

ER -